D89.81 Graft-versus-host disease

Name of the Condition

• Graft-versus-host disease

Summary

Graft-versus-host disease (GVHD) is an immune-mediated condition that occurs when transplanted immune cells (graft) attack the recipient’s tissues (host). It typically arises after allogeneic hematopoietic stem cell transplantation but can also occur in other settings, such as blood product transfusions. The condition can affect multiple organ systems, with skin, gastrointestinal tract, and liver being the most commonly involved. Acute and chronic forms exist, distinguished by timing and clinical features.

Causes

GVHD is caused by donor immune cells recognizing the recipient’s tissues as foreign and mounting an immune response. In allogeneic transplantation, this occurs when the graft contains functional T cells that react against the host’s histocompatibility antigens. The risk increases with greater HLA mismatch between donor and recipient. Non-transplant-related GVHD may occur after transfusions in immunocompromised patients, where donor lymphocytes engraft and attack the host.

Risk Factors

• Allogeneic hematopoietic stem cell transplantation
• HLA mismatch between donor and recipient
• Older age of the recipient
• Female donors for male recipients (due to prior pregnancies)
• Intensity of conditioning regimens
• Use of peripheral blood stem cells (vs. bone marrow)
• Prior episodes of acute GVHD

Symptoms

• Skin: Rash, erythema, desquamation, or blistering
• Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain
• Liver: Elevated bilirubin, jaundice, or hepatomegaly
• Eyes: Dryness, redness, or photophobia
• Lungs: Dyspnea or cough (in severe cases)
• Musculoskeletal: Joint pain or stiffness (chronic GVHD)

Diagnosis

Diagnosis is based on clinical presentation and histopathological confirmation. Skin biopsies show interface dermatitis; gastrointestinal biopsies reveal epithelial cell apoptosis. Liver involvement is assessed via elevated transaminases and bilirubin, with biopsy showing bile duct damage. Chronic GVHD may require additional evaluation for fibrotic changes or autoimmune phenomena. Staging and severity grading guide management.

Treatment Options

• Acute GVHD: High-dose corticosteroids (first-line), calcineurin inhibitors, or monoclonal antibodies (e.g., anti-IL-2 receptor)
• Chronic GVHD: Topical or systemic immunosuppressants (e.g., tacrolimus, mycophenolate), phototherapy, or rituximab
• Supportive care: Skin moisturizers, nutritional support, or bile acid sequestrants for liver involvement
• Refractory cases: Experimental therapies (e.g., JAK inhibitors) or extracorporeal photopheresis

Prognosis and Follow-Up

Prognosis depends on the form, severity, and organ involvement. Acute GVHD with multi-organ involvement has higher mortality, while limited chronic GVHD may have better outcomes with long-term management. Regular monitoring for organ function, infection risk, and treatment toxicities is essential. Long-term follow-up focuses on preventing late complications, such as secondary malignancies or organ fibrosis.

Complications

• Infection due to immunosuppression
• Organ fibrosis (e.g., pulmonary, hepatic)
• Malnutrition or gastrointestinal obstruction
• Secondary autoimmune disorders
• Transplant-related mortality
• Reduced quality of life from chronic symptoms

Lifestyle & Prevention

• Pre-transplant HLA matching to minimize risk
• Post-transplant prophylaxis (e.g., methotrexate, cyclosporine)
• Sun protection and skin care for chronic GVHD
• Nutritional support to maintain weight and hydration
• Vaccination schedules adjusted for immunosuppression
• Avoidance of potential triggers (e.g., infections, allergens)

When to Seek Professional Help

Seek immediate care for:

• Severe diarrhea, vomiting, or abdominal pain
• Rapidly spreading skin rash or blistering
• Jaundice or dark urine
• Shortness of breath or chest pain
• Signs of infection (e.g., fever, chills)

Tips for Medical Coders

Code D89.81 is specific to graft-versus-host disease and should be assigned when the condition is documented, regardless of acute or chronic classification. Ensure documentation specifies the setting (e.g., post-transplant) and organ involvement, as this may impact coding for related complications. Do not use this code for other immune-mediated disorders; verify the clinical context to avoid misclassification.